Generer rapport
Nodus Oncology Aps
Bredgade 3, 3, c/o BACH Advokater, 1260 København K, CVR 43510045
Virksomhedsform
Anpartsselskab
Etableret
2022
Størrelse
Mikro
Ansatte
-
Omsætning
-
DKK
Bruttofortj.
-47.979
DKK
Primært resultat (EBIT)
-47.979
DKK
Årets resultat
-47.979
DKK
Egenkapital
-7.979
DKK
annonce
Flere nøgletal og analyser?
Med en Bisbase Premium konto får du flere nøgletal for både virksomheder, koncerner og brancher samt adgang til eksklusive brancher indeholdende virksomheder nøje sammensat af eksperter. Og vil du lave dine egne analyser kan du også det! Det tager få minutter at få adgang - og det behøver ikke at koste dig noget!
Rang Årets resultat
Rang i branche
79/161
"Omkring gns"
Rang i Danmark
268.291/343.417
"Bund 35%"
Direktion top 3
| Ian David Waddell 1 | Direktør |
Bestyrelse top 3
| Clare Jane Platt 1 | Bestyrelsesmedlem |
| Julia Mary Brown 1 | Bestyrelsesmedlem |
| Luis Ignacio Toledo Lazaro 2 | Bestyrelsesmedlem |
Legale ejere top 3
| 100% | NODUS ONCOLOGY LIMITED | GB |
Tegningsregler
Selskabet tegnes af den samlede bestyrelse eller af én direktør.
Stamoplysninger baseret på CVR
| Navn | Nodus Oncology Aps |
| CVR | 43510045 |
| Adresse | Bredgade 3, 3, c/o BACH Advokater, 1260 København K |
| Branche | Fremstilling af farmaceutiske præparater [212000] |
| Etableret | 12-09-2022 (1 år) |
| Første regnskabsperiode | 12-09-2022 til 31-12-2023 |
| Virksomhedsform | Anpartsselskab |
| Antal ansatte | - |
| Reklamebeskyttelse | Nej |
| Revision fravalgt | Ja |
| Regnskabsperiode | 01-01 til 31-12 |
| Selskabskapital | 40.000 DKK |
| Vedtægter seneste | 12-09-2022 |
Medlem af brancherne
- Fremstilling af farmaceutiske præparaterNACE6 indeholdende 205 virk.
- Fremstilling af farmaceutiske præparaterNACE3 indeholdende 205 virk.
- Fremstilling af farmaceutiske råvarer og farmaceutiske præparaterNACE2 indeholdende 243 virk.
- FremstillingsvirksomhedNACE1 indeholdende 26.276 virk.
Formål
Selskabets formål er at udvikle lægemidler og hermed forbundet virksomhed.
Regnskab
| 2023 | |
|---|---|
| Valuta/enhed | 000' DKK |
| Omsætning | - - |
| Bruttofortjeneste | -48 - |
| Årets resultat | -48 - |
| Egenkapital | -8 - |
| Balance | 40 - |
Ledelsesberetning
Principal activities
The company's objective is to develop pharmaceuticals and any other such related business.
Development in activities and economic conditions
The Company has been dormant doing the finacial year and considers the result for the first financial period to be in line with expectations.
The Company has lost all of the share capital. The management expects the share capital to be restored through the Company's future operations. The Company has received a letter of support from the shareholders.
Events after the end of the financial period
No events have occurred after the end of the financial period that may have a significant impact on the financial position of the Company.
The Company has been dormant doing the finacial year and considers the result for the first financial period to be in line with expectations. The Company has lost all of the share capital. The management expects the share capital to be restored through the Company's future operations. The Company has received a letter of support from the shareholders. , Development in activities and economic conditions The Company has been dormant doing the finacial year and considers the result for the first financial period to be in line with expectations. The Company has lost all of the share capital. The management expects the share capital to be restored through the Company's future operations. The Company has received a letter of support from the shareholders.
The Company has been dormant doing the finacial year and considers the result for the first financial period to be in line with expectations. The Company has lost all of the share capital. The management expects the share capital to be restored through the Company's future operations. The Company has received a letter of support from the shareholders. , Development in activities and economic conditions The Company has been dormant doing the finacial year and considers the result for the first financial period to be in line with expectations. The Company has lost all of the share capital. The management expects the share capital to be restored through the Company's future operations. The Company has received a letter of support from the shareholders.
26-03-2024